Moody National Bank Trust Division lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 43.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,913 shares of the company’s stock after selling 3,062 shares during the period. Moody National Bank Trust Division’s holdings in AstraZeneca were worth $259,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. DB Wealth Management Group LLC bought a new position in AstraZeneca during the first quarter worth about $26,000. Parkside Financial Bank & Trust raised its position in shares of AstraZeneca by 4,875.0% during the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after purchasing an additional 390 shares during the period. Baltimore Washington Financial Advisors Inc. acquired a new stake in shares of AstraZeneca during the fourth quarter worth about $27,000. Fairfield Bush & CO. acquired a new stake in shares of AstraZeneca during the first quarter worth about $28,000. Finally, Quent Capital LLC acquired a new stake in shares of AstraZeneca during the fourth quarter worth about $31,000. Institutional investors own 21.55% of the company’s stock.
AstraZeneca Price Performance
Shares of NASDAQ AZN opened at $57.40 on Wednesday. The company has a current ratio of 0.96, a quick ratio of 0.67 and a debt-to-equity ratio of 0.74. AstraZeneca PLC has a 12 month low of $53.63 and a 12 month high of $71.70. The stock has a 50 day moving average of $64.20 and a 200-day moving average of $64.85.
AstraZeneca Cuts Dividend
Analysts Set New Price Targets
AZN has been the topic of a number of research analyst reports. StockNews.com raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Monday, July 11th. Credit Suisse Group lowered AstraZeneca from an “outperform” rating to a “neutral” rating in a research report on Thursday, September 15th. AlphaValue raised AstraZeneca to a “reduce” rating in a research report on Monday, August 22nd. Morgan Stanley lowered AstraZeneca from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, September 7th. Finally, TheStreet lowered AstraZeneca from a “b-” rating to a “c” rating in a research report on Tuesday, August 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8,840.50.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.